MIRA INFORM REPORT

 

 

Report Date :

13.09.2012

 

IDENTIFICATION DETAILS

 

Name :

BRISTOL LABORATORIES LTD.

 

 

 

 

Registered Office :

Unit 3 Canalside North Bridge Road Berkhamsted, HP4 1EG

 

 

 

 

Country :

United Kingdom

 

 

 

 

Financials (as on) :

30.06.2011

 

 

 

 

Date of Incorporation :

27.06.1997

 

 

 

 

Com. Reg. No.:

03393503

 

 

 

 

Legal Form :

Private Subsidiary

 

 

 

 

Line of Business :

Wholesale of pharmaceutical goods

 

 

 

 

No. of Employees :

174

 

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Status :

Satisfactory

Payment Behaviour :

No Complaints

Litigation :

Clear

NOTES :

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

 

ECGC Country Risk Classification List – March 31st, 2012

 

Country Name

Previous Rating

(31.12.2011)

Current Rating

(31.03.2012)

United Kingdom

A1

A1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

UNITED KINGDOM - ECONOMIC OVERVIEW

 

The UK, a leading trading power and financial center, is the third largest economy in Europe after Germany and France. Over the past two decades, the government has greatly reduced public ownership and contained the growth of social welfare programs. Agriculture is intensive, highly mechanized, and efficient by European standards, producing about 60% of food needs with less than 2% of the labor force. The UK has large coal, natural gas, and oil resources, but its oil and natural gas reserves are declining and the UK became a net importer of energy in 2005. Services, particularly banking, insurance, and business services, account by far for the largest proportion of GDP while industry continues to decline in importance. After emerging from recession in 1992, Britain's economy enjoyed the longest period of expansion on record during which time growth outpaced most of Western Europe. In 2008, however, the global financial crisis hit the economy particularly hard, due to the importance of its financial sector. Sharply declining home prices, high consumer debt, and the global economic slowdown compounded Britain's economic problems, pushing the economy into recession in the latter half of 2008 and prompting the then BROWN (Labour) government to implement a number of measures to stimulate the economy and stabilize the financial markets; these include nationalizing parts of the banking system, temporarily cutting taxes, suspending public sector borrowing rules, and moving forward public spending on capital projects. Facing burgeoning public deficits and debt levels, in 2010 the CAMERON-led coalition government (between Conservatives and Liberal Democrats) initiated a five-year austerity program, which aims to lower London's budget deficit from over 10% of GDP in 2010 to nearly 1% by 2015. In November 2011, Chancellor of the Exchequer George OSBORNE announced additional austerity measures through 2017 because of slower-than-expected economic growth and the impact of the euro-zone debt crisis. The CAMERON government raised the value added tax from 17.5% to 20% in 2011. It has pledged to reduce the corporation tax rate to 23% by 2015. The Bank of England (BoE) implemented an asset purchase program of up to £325 billion (approximately $525 billion) as of February 2011. During times of economic crisis, the BoE coordinates interest rate moves with the European Central Bank, but Britain remains outside the European Economic and Monetary Union (EMU).

Source : CIA


Company name and address

 

Top of Form

Bottom of Form

Bristol Laboratories Ltd.

                                                                                                                                                   

 

Unit 3 Canalside

North Bridge Road

 

Berkhamsted, HP4 1EG

United Kingdom

 

 

Tel:

01442 200922

 

www.bristol-labs.co.uk

 

Employees:

174

Company Type:

Private Subsidiary

Corporate Family:

2 Companies

Ultimate Parent:

Brl Investments Ltd.

 

 

Quoted Status:

Non-quoted Company

Incorporation Date:

27-Jun-1997

Auditor:

King And King

Financials in:

USD (mil)

 

 

Fiscal Year End:

30-Jun-2011

Reporting Currency:

British Pound Sterling

Annual Sales:

107.4  1

Net Income:

5.7

Total Assets:

66.3

                                      

Business Description       

 

Manufacturing and distribution of pharmaceutical products.

     

Industry                                                                 

 

Industry

Personal and Household Products

ANZSIC 2006:

3720 - Pharmaceutical and Toiletry Goods Wholesaling

NACE 2002:

5146 - Wholesale of pharmaceutical goods

NAICS 2002:

424210 - Drugs and Druggists' Sundries Merchant Wholesalers

UK SIC 2003:

5146 - Wholesale of pharmaceutical goods

UK SIC 2007:

4646 - Wholesale of pharmaceutical goods

US SIC 1987:

5122 - Drugs, Drug Proprietaries, and Druggists' Sundries

  Key Executives         

   

 

Name

Title

Sreekumar Kaduporath Nair

Secretary

Raju Puthenvilayil Mathaikutty

Director

Ramachandran Thembalath

Director

           

News    

 

Title

Date

Retrophin Names Stephen Aselage as Chief Executive Officer
Business Wire (487 Words)

10-Sep-2012

HILLERS
Post-Standard (Syracuse, NY) (285 Words)

30-Aug-2012

KOTAS
Post-Standard (Syracuse, NY) (144 Words)

6-Jun-2012

LAZZARO
Post-Standard (Syracuse, NY) (235 Words)

19-May-2012

STAAB
Post-Standard (Syracuse, NY) (275 Words)

2-Feb-2012

   

Financial Summary                                                                          

 

FYE: 30-Jun-2011

USD (mil)

Key Figures

 

Current Assets

45.65

Fixed Assets

20.63

Total Liabilities

41.03

Net Worth

14.03

 

Key Ratios

 

Current Ratio

1.11

Acid Test

0.76

Debt Gearing

41.49

 

 

1 - Profit & Loss Item Exchange Rate: USD 1 = GBP 0.6291059
2 - Balance Sheet Item Exchange Rate: USD 1 = GBP 0.6228783

 

 

Corporate Overview

 

Location
Unit 3 Canalside
North Bridge Road
Berkhamsted, HP4 1EG
Hertfordshire County
United Kingdom

 

Tel:

01442 200922

 

www.bristol-labs.co.uk

Sales GBP(mil):

67.6

Assets GBP(mil):

41.3

Employees:

174

Fiscal Year End:

30-Jun-2011

 

Industry:

Personal and Household Products

Registered Address:
Unit 3 Canalside
North Bridge Road
Berkhamsted, HP4 1EG
United Kingdom

 

Incorporation Date:

27-Jun-1997

Company Type:

Private Subsidiary

Quoted Status:

Not Quoted

Registered No.(UK):

03393503

 

Director:

Ramachandran Thembalath

Contents

Industry Codes

Business Description

Financial Data

Key Corporate Relationships

Industry Codes

 

ANZSIC 2006 Codes:

3720

-

Pharmaceutical and Toiletry Goods Wholesaling

 

NACE 2002 Codes:

5146

-

Wholesale of pharmaceutical goods

 

NAICS 2002 Codes:

424210

-

Drugs and Druggists' Sundries Merchant Wholesalers

 

US SIC 1987:

5122

-

Drugs, Drug Proprietaries, and Druggists' Sundries

 

UK SIC 2003:

5146

-

Wholesale of pharmaceutical goods

 

UK SIC 2007:

4646

-

Wholesale of pharmaceutical goods

 

Business Description

Manufacturing and distribution of pharmaceutical products.

.

More Business Descriptions

Pharmaceutical Products Manufacturers

 

 

 

 

 

 

 

 

Financial Data

 

Financials in:

GBP(mil)

 

Revenue:

67.6

Net Income:

3.6

Assets:

41.3

Current Assets:

28.4

 

Fixed Assets:

12.9

 

Long Term Debt:

6.9

 

Total Liabilities:

32.5

 

Issued Capital:

0.1

 

Working Capital:

2.9

 

Net Worth:

8.7

 

 

 

Date of Financial Data:

30-Jun-2011

 

1 Year Growth

18.4%

NA

NA

 

Key Corporate Relationships

Auditor:

King And King

Bank:

Barclays Bank PLC

 

Auditor:

King And King

 

 

 

GBP(mil)

Audit Fees:

0.0

Non Audit Fees:

0.0

Audit Fiscal Year:

06-30-2011

 

 

 

 

 

 

Corporate Structure News

 

Bristol Laboratories Ltd.
Total Corporate Family Members: 2

 

 

 

 

Company Name

Company Type

Location

Country

Industry

Sales
(USD mil)

Employees

Brl Investments Ltd.

Parent

 

 

 

 

 

Bristol Laboratories Ltd.

Subsidiary

Berkhamsted

United Kingdom

Personal and Household Products

107.4

174

 

 

 

 

 

Executives Report

 

 

Board of Directors

 

Name

Title

Function

Raju Puthenvilayil Mathaikutty

 

Director

Director/Board Member

Age: 56

.

Ramachandran Thembalath

 

Director

Director/Board Member

 

 

Age: 62

 

 

Executives

 

Name

Title

Function

Sreekumar Kaduporath Nair

 

Secretary

Company Secretary

Age: 54

 

 

 

Directors and Shareholders Report

 

Annual Return Date: 27 Jun 2012
Total Issued Capital (GBP 000): 100

 

Individual Directors


 

Name

Status

DOB

Filed Address

Appointment Date

Resignation Date

Summary of Directorships

 

Sreekumar
Kaduporath Nair

Current

31 Jul 1958

16 Seamarks Court, 1A Kingsway,
Luton, Bedfordshire LU4 8DT

27 Apr 2006

NA

Current:2
Previous:0
Disqualifications:0

 

Ramachandran
Thembalath

Current

30 Nov 1949

Cambridge House Batchworth Lane,
Northwood, Middlesex HA6 2AT

01 Nov 2008

NA

Current:1
Previous:0
Disqualifications:0

 

Raju
Puthenvilayil Mathaikutty

Current

11 May 1956

Sherwood Green, Manor House Drive,
Northwood, Middlesex HA6 2UJ

27 Jun 1997

NA

Current:1
Previous:0
Disqualifications:0

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate Directors


 

Company Name

Status

Registered Address

Appointment Date

Resignation Date

First Directors Limited

Previous

72 New Bond Street,
London , London W1S 1RR

27 Jun 1997

27 Jun 1997

 

 

 

 

Individual Secretaries


 

Name

Status

DOB

Filed Address

Appointment Date

Resignation Date

Summary of Directorships

 

Sreekumar
Kaduporath Nair

Current

31 Jul 1958

16 Seamarks Court, 1A Kingsway,
Luton, Bedfordshire LU4 8DT

27 Apr 2006

NA

Current:2
Previous:0
Disqualifications:0

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate Secretaries


 

Company Name

Status

Registered Address

Appointment Date

Resignation Date

First Secretaries Limited

Previous

72 New Bond Street,
London , London W1S 1RR

27 Jun 1997

07 Jun 2006

 

 

 

 

Individual Shareholders


 

Name

Share Details
(As Reported)

Share Type

# of Shares

Share Price (GBP)

Share Value (GBP)

% of Total Shares

BRL Holdings Limited

24000 Ordinary GBP 1.00

Ordinary

24,000

1.00

24,000.00

24.00

BRL Investments Limited

76000 Ordinary GBP 1.00

Ordinary

76,000

1.00

76,000.00

76.00

 

 

 

 

 

 

 

 

Corporate Shareholders


 

There are no corporate shareholders for this company.

 

 

 

Annual Profit & Loss

 

Financials in: USD (mil)

 

Except for share items (millions) and per share items (actual units)

 

 

 

 

 

 

 

30-Jun-2011

30-Jun-2010

30-Jun-2009

30-Jun-2008

30-Jun-2007

Period Length

52 Weeks

52 Weeks

52 Weeks

52 Weeks

52 Weeks

Filed Currency

GBP

GBP

GBP

GBP

GBP

Exchange Rate (Period Average)

0.629106

0.633607

0.627423

0.499214

0.517836

Consolidated

No

No

No

No

No

 

 

 

 

 

 

Turnover (UK)

96.9

81.2

59.9

61.5

-

Turnover (Exports)

10.5

8.8

8.8

9.9

-

Total Turnover

107.4

90.1

68.7

71.4

-

Cost of Sales

89.1

77.2

59.5

62.6

-

Gross Profit

18.3

12.9

9.2

8.8

7.0

Depreciation

1.6

1.7

1.2

1.4

1.0

Other Expenses

10.0

8.7

6.8

7.2

5.7

Operating Profit

-

-

2.4

1.6

1.3

Other Income

0.0

0.0

0.0

0.0

0.0

Interest Paid

0.3

0.3

0.4

0.5

0.6

Exceptional Income

0.0

0.0

0.0

0.0

0.0

Discontinued Operations

0.0

0.0

0.0

0.0

0.0

Profit Before Taxes

8.1

3.9

2.0

1.0

0.8

Tax Payable / Credit

1.9

1.0

0.5

0.3

0.1

Extraordinary Items/Debits

0.0

0.0

0.0

0.0

0.0

Dividends

0.5

0.0

0.2

0.2

0.0

Profit After Taxes

5.7

2.9

1.4

0.6

0.7

Minority Interests (Profit & Loss)

0.0

0.0

0.0

0.0

0.0

Audit Fees

0.0

0.0

0.0

0.0

0.0

Non Audit Fees

0.0

0.0

0.0

0.0

0.0

Number of Employees

174

149

137

132

114

Wages

6.8

5.8

4.9

5.4

4.0

Social Security Costs

0.5

0.3

0.3

0.4

0.3

Pensions

-

-

-

0.0

-

Other Pension Costs

0.6

0.7

0.0

0.1

0.1

Employees Remuneration

7.9

6.8

5.2

5.8

4.4

Directors Emoluments

-

-

-

0.2

-

Other Costs

-

-

-

0.0

-

Directors Remuneration

0.5

0.5

0.5

0.2

0.2

Highest Paid Director

0.3

0.3

0.3

-

-

 

 

 

Annual Balance Sheet

Financials in: USD (mil)

 

 

 

30-Jun-2011

30-Jun-2010

30-Jun-2009

30-Jun-2008

30-Jun-2007

Filed Currency

GBP

GBP

GBP

GBP

GBP

Exchange Rate

0.622878

0.668405

0.60722

0.502475

0.498418

Consolidated

No

No

No

No

No

 

 

 

 

 

 

Land & Buildings

16.4

-

-

10.0

9.3

Fixtures & Fittings

0.3

-

-

0.2

0.2

Plant & Vehicles

4.0

-

-

2.8

2.4

Total Tangible Fixed Assets

20.6

17.8

15.7

12.9

12.0

Intangible Assets

0.0

0.0

0.0

0.0

0.0

Investments

0.0

0.0

0.0

0.0

0.0

Total Fixed Assets

20.6

17.8

15.8

13.0

12.1

Stocks

13.8

12.1

9.2

8.0

4.7

Work in Progress

0.7

0.4

0.3

0.6

0.6

Total Stocks Work In Progress

14.5

12.5

9.4

8.6

5.3

Trade Debtors

23.4

13.7

17.2

19.0

20.6

Inter-Company Debtors

0.7

0.0

0.5

0.0

0.0

Director Loans

-

-

-

0.0

0.0

Other Debtors

4.9

0.8

0.7

0.8

0.9

Total Debtors

29.0

14.6

18.4

19.8

21.5

Cash and Equivalents

0.9

1.3

1.5

0.4

0.2

Other Current Assets

1.2

1.1

0.0

0.0

0.0

Total Current Assets

45.6

29.5

29.4

28.8

27.0

Total Assets

66.3

47.3

45.2

41.8

39.0

Trade Creditors

30.2

21.6

23.8

20.9

21.6

Bank Overdraft

1.6

4.8

2.0

5.8

2.5

Inter-Company Creditors

-

0.0

-

-

-

Director Loans (Current Liability)

-

0.0

-

0.0

0.0

Hire Purchase (Current Liability)

-

0.0

-

-

-

Finance Lease (Current Liability)

-

0.0

-

-

-

Total Finance Lease/Hire Purchase (Current Liability)

-

0.0

-

-

-

Total Short Term Loans

-

0.0

-

-

0.3

Accruals/Deferred Income (Current Liability)

7.1

1.8

1.6

1.1

1.0

Social Security/VAT

0.2

0.0

0.5

0.2

0.7

Corporation Tax

1.7

1.0

0.5

0.3

0.1

Dividends (Current Liability)

-

0.0

-

-

-

Other Current Liabilities

0.1

0.0

0.3

0.3

0.4

Total Current Liabilities

41.0

29.2

28.6

28.5

26.5

Group Loans (Long Term Liability)

0.0

-

0.0

1.0

0.0

Director Loans (Long Term Liability)

0.0

-

0.0

0.0

0.0

Hire Purchase (Long Term Liability)

0.0

0.0

0.0

0.0

0.0

Leasing (Long Term Liability)

0.0

0.0

0.0

0.0

0.0

Total Hire Purchase Loans (Long Term Liability)

0.0

0.0

0.0

0.0

0.0

Other Long Term Loans

5.8

9.0

9.7

5.4

8.1

Accruals/Deferred Income (Long Term Liability)

5.3

0.0

0.0

0.0

0.0

Other Long Term Liabilities

0.0

1.2

1.4

1.9

0.8

Total Long Term Liabilities

11.1

10.3

11.0

8.3

8.9

Deferred Taxation

0.1

0.1

0.1

0.1

0.1

Other Provisions

0.0

0.0

0.0

0.0

0.0

Total Provisions

0.1

0.1

0.1

0.1

0.1

Issued Capital

0.2

0.1

0.2

0.2

0.2

Share Premium Accounts

0.0

0.0

0.0

0.0

0.0

Revaluation Reserve

0.6

0.6

0.7

0.8

0.0

Retained Earnings

13.2

7.0

4.6

3.9

3.3

Other Reserves

0.0

0.0

0.0

0.0

0.0

Minority Interests (Balance Sheet)

0.0

0.0

0.0

0.0

0.0

Total Shareholders Funds

14.0

7.7

5.5

4.9

3.5

Net Worth

14.0

7.7

5.5

4.9

3.5

 

 

 

Annual Cash Flows

Financials in: USD (mil)

 

 

 

30-Jun-2011

30-Jun-2010

30-Jun-2009

30-Jun-2008

30-Jun-2007

Period Length

52 Weeks

52 Weeks

52 Weeks

52 Weeks

52 Weeks

Filed Currency

GBP

GBP

GBP

GBP

GBP

Exchange Rate (Period Average)

0.629106

0.633607

0.627423

0.499214

0.517836

Consolidated

No

No

No

No

No

 

 

 

 

 

 

Net Cash Flow From Operating Activities

8.1

3.8

6.6

0.6

-0.1

Net Cash Flow from ROI and Servicing of Finance

-0.3

-0.3

-0.4

-0.5

-0.6

Taxation

-1.3

-0.4

-0.2

-0.1

-0.1

Capital Expenditures

-3.2

-6.5

-6.0

-1.7

-0.5

Acquisitions and Disposals

0.0

0.0

0.0

0.0

0.0

Paid Up Equity

-0.5

0.0

-0.2

-0.2

0.0

Management of Liquid Resources

0.0

0.0

0.0

0.0

0.0

Net Cash Flow From Financing

0.6

0.1

4.7

-0.5

-0.5

Increase in Cash

3.4

-3.4

4.6

-2.4

-1.7

 

 

 

Annual Ratios

Financials in: USD (mil)

 

 

 

 

 

30-Jun-2011

30-Jun-2010

30-Jun-2009

30-Jun-2008

30-Jun-2007

Period Length

52 Weeks

52 Weeks

52 Weeks

52 Weeks

52 Weeks

Filed Currency

GBP

GBP

GBP

GBP

GBP

Exchange Rate

0.622878

0.668405

0.60722

0.502475

0.498418

Consolidated

No

No

No

No

No

 

 

 

 

 

 

Current Ratio

1.11

1.01

1.03

1.01

1.02

Liquidity Ratio

0.76

0.58

0.70

0.71

0.82

Stock Turnover

7.49

6.83

7.52

8.25

-

Credit Period (Days)

78.76

58.63

88.49

97.82

-

Working Capital by Sales

4.26%

0.36%

1.17%

0.45%

-

Trade Credit by Debtors

1.29

1.57

1.38

1.10

1.05

Return on Capital

32.27%

20.57%

12.41%

7.75%

6.25%

Return on Assets

12.30%

7.86%

4.56%

2.47%

2.00%

Profit Margin

7.51%

4.35%

2.90%

1.45%

-

Return on Shareholders Funds

58.10%

48.05%

37.70%

21.15%

22.12%

Borrowing Ratio

52.89%

178.91%

213.38%

250.85%

309.81%

Equity Gearing

21.16%

16.36%

12.09%

11.67%

9.06%

Debt Gearing

41.49%

116.78%

177.08%

132.15%

230.93%

Interest Coverage

27.90

12.89

5.44

1.91

1.30

Sales by Tangible Assets

5.26

4.81

4.51

5.48

-

Average Remuneration per Employee

0.0

0.0

0.0

0.0

0.0

Profit per Employee

0.0

0.0

0.0

0.0

0.0

Sales per Employee

0.6

0.6

0.5

0.5

-

Capital Employed per Employee

0.1

0.1

0.1

0.1

0.1

Tangible Assets per Employee

0.1

0.1

0.1

0.1

0.1

Total Assets per Employee

0.4

0.3

0.3

0.3

0.3

Employee Remuneration by Sales

7.33%

7.52%

7.59%

8.14%

-

Creditor Days (Cost of Sales Based)

122.49

107.75

141.07

122.67

-

Creditor Days (Sales Based)

101.61

92.32

122.18

107.55

-

 

 

Bottom of Form

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.55.26

UK Pound

1

Rs.88.85

Euro

1

Rs.71.13

 

 

INFORMATION DETAILS

 

Report Prepared by :

PRL

 

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

--

NB

New Business

 

--

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.